Biostax

Biostax ROIC

The Return on Invested Capital (ROIC) of Biostax (BTAX) as of Nov 1, 2026 is 69.52 %. In the previous year, Return on Invested Capital (ROIC) was 194.61 % — a change of -64.28% (lower).

ROIC

69.52 %

YoY

-64.28%

Last updated:

Return on Invested Capital (ROIC) of Biostax is 2023 69.52 % . Return on Invested Capital (ROIC) of Biostax was 2022 194.61 % . It decreases by -64.28% lower compared to the previous year.

The Biostax ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2016
2,148.51 USD
Jan 1, 2017
436.87 USD
Jan 1, 2018
134.84 USD
Jan 1, 2019
24.81 USD
Jan 1, 2020
-18.01 USD
Jan 1, 2021
-73.51 USD
Jan 1, 2022
194.61 USD
Jan 1, 2023
69.52 USD
The Biostax ROIC history
YEARROICYoY
69.52 %-64.28%
194.61 %-364.73%
-73.51 %+308.25%
-18.01 %-172.57%
24.81 %-81.60%
134.84 %-69.13%
436.87 %-79.67%
2,148.51 %+60.51%
1,338.58 %-162.68%
-2,135.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostax Stock analysis

What does Biostax do? Immune Therapeutics, Inc. develops and markets pharmaceutical, biotechnology, and MedTech products through its subsidiary BiostaxRx, which focuses on treating inflammaging disease. The company's product portfolio includes Londonal, a once-a-day immune system regulator for HIV/AIDS management, and JKB-122, a therapy targeting Autoimmune Hepatitis, NAFLD, and NASH with anti-fibrotic and anti-inflammatory properties. Biostax has partnerships in autoimmunity and immune restoration fields to deliver solutions for patients with autoimmunity, chronic inflammation, infection, and cancer. BiostaxRx specifically addresses inflammaging disease within its treatment focus. Biostax Corp's revenue streams come from the sale of Londonal and JKB-122 to healthcare providers and patients seeking treatments for immune-related conditions. The company markets its products to medical professionals and institutions specializing in autoimmune disorders, chronic inflammation, and oncology. Its focus on specific therapeutic areas allows it to target healthcare segments requiring immune modulation and anti-inflammatory solutions. The company's partnerships support its delivery of specialized treatments for chronic conditions such as HIV/AIDS, liver diseases, and cancer-related inflammation. The company's product lines are designed for specific patient segments including those with HIV/AIDS, Autoimmune Hepatitis, NAFLD, NASH, and inflammaging. Londonal is positioned for HIV/AIDS management while JKB-122 targets liver conditions and inflammation. BiostaxRx's focus on inflammaging disease aligns with the growing market for age-related immune health solutions. The company's marketing strategy emphasizes specialized treatments for complex conditions where current therapies are limited or ineffective. Biostax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostax stock

Return on Invested Capital (ROIC) of Biostax is 69.52 % in 2023.

Return on Invested Capital (ROIC) of Biostax changed from 194.61 % to 69.52 %, representing a -64.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Biostax since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Biostax with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biostax

All Key Metrics — Biostax